XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Stock Option Plans
12 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Share-based Payment Arrangement [Text Block]

17.                Stock Option Plans


In December 2016, the Board adopted the 2016 Stock Option Plan (the “2016 Plan”) which reserved for issuance options to purchase up to 250,000 shares of its Common Stock.  The stockholders approved the Plan at the January 2017 annual meeting. Shareholders had previously adopted the 2006 Stock Option Plan, under which substantially all of the options have been granted. Therefore, the Board approved the 2016 Plan, and the terms are substantially the same as under the 2006 Employees Stock Option. The 2016 Plan reserves for issuance options to purchase up to 250,000 shares of its common stock. All employees, directors and consultants are eligible to receive stock option grants under this plan. The 2016 Plan, which has a term of ten years from the date of adoption, is administered by the Board or by a committee appointed by the Board. The selection of participants, allotment of shares, and other conditions related to the grant of options, to the extent not set forth in the Plan, are determined by the Board. Options granted under the Plan are exercisable up to a period of five years from the date of grant at an exercise price which is not less than the fair market value of the common stock at the date of grant, except to a shareholder owning 10% or more of the outstanding common stock of the Company, as to which the exercise price must be not less than 110% of the fair market value of the common stock at the date of grant. Options, for the most part, are exercisable on a cumulative basis, 20% at or after each of the first, second, and third anniversary of the grant and 40% after the fourth year anniversary.


The fair value of each option awarded is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of Common Stock. The expected life of the options granted represents the period of time from date of grant to expiration (5 years). The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. There were no stock options granted for the year ended March 31, 2019. The per share weighted-average fair value of stock options granted for the year ended March 31, 2020 was $1.05 on the date of grant using the Black Scholes option-pricing model with the following assumptions:


 

 

Dividend

 

 

Risk-free

 

 

 

 

 

 

 

 

 

Yield

 

 

Interest rate

 

 

Volatility

 

 

Life

2020

 

 

0.0

%

 

 

2.28

%

 

 

33.15

%

 

5 years


A summary of the status of the Company’s stock option plans for the fiscal years ended March 31, 2020 and 2019 and changes during the years are presented below (in number of options):


   

Number of

Options

   

Average

Exercise Price

 

Average Remaining

Contractual Term

 

Aggregate

Intrinsic Value

 

Outstanding options at April 1, 2018

    72,500     $ 5.26            

Options granted

    -     $ -            

Options exercised

    -     $ -            

Options canceled/forfeited

    (30,000

)

  $ 5.07            
                           

Outstanding options at March 31, 2019

    42,500     $ 5.40  

1.6 years

  $ -0-  

Options granted

    76,000     $ 3.19            

Options exercised

    -     $ -            

Options canceled/forfeited

    -     $ -            
                           

Outstanding options at March 31, 2020

    118,500     $ 3.98  

2.8 years

  $ 13,295  

Vested Options:

                         

      March 31, 2020:

    38,000     $ 5.65  

0.3 years

  $ 2,734-  

      March 31, 2019:

    22,500     $ 5.68  

1.3 years

  $ -0-  

Remaining options available for grant were 166,500 and 242,500 as of March 31, 2020 and 2019, respectively.


For the years ended March 31, 2020 and 2019, the unamortized compensation expense for stock options was $61,592 and $9,612, respectively. Unamortized compensation expense is expected to be recognized over a weighted-average period of approximately 1 year.


A summary of the Company’s non-vested shares as of March 31, 2020 and changes during the year ended March 31, 2020 is presented below:


Non-vested Shares

 

Shares

   

Weighted-Average

Grant-Date

Fair value

 
                 

Non-vested at April 1, 2019

    20,000     $ 5.09  

Granted

    76,000     $ 3.19  

Vested

    (15,500

)

  $ 5.60  

Forfeited

          $ -  

Non-vested at March 31, 2020

    80,500     $ 3.20  

The compensation cost that has been charged was $21,669 and $24,016 for the fiscal years ended March 31, 2020 and 2019, respectively.